{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:57:52Z","timestamp":1793656672368,"version":"4.5.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2026621"],"award-info":[{"award-number":["2026621"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009860","name":"Ramaciotti Foundations","doi-asserted-by":"publisher","award":["2023HIG69"],"award-info":[{"award-number":["2023HIG69"]}],"id":[{"id":"10.13039\/100009860","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ekir.2025.01.029","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T21:54:04Z","timestamp":1738187644000},"page":"1037-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-7575","authenticated-orcid":false,"given":"Bernard","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil V.","family":"Badve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murilo","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Arnott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kozor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"O\u2019Lone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sradha","family":"Kotwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.01.029_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ckj\/sfz091","article-title":"Anemia and iron deficiency among chronic kidney disease Stages 3\u20135ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: Often unmeasured, variably treated","volume":"13","author":"Wong","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.01.029_bib2","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1681\/ASN.2020101531","article-title":"Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without anemia","volume":"32","author":"Guedes","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib3","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ndt\/gfab050","article-title":"Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia","volume":"36","author":"Guedes","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib5","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","article-title":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: An individual patient data meta-analysis","volume":"44","author":"Ponikowski","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2025.01.029_bib6","first-page":"5","article-title":"Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"26","author":"Members","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ekir.2025.01.029_bib7","first-page":"279","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2025.01.029_bib8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.01.029_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.01.029_bib10","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.ekir.2021.05.020","article-title":"Treatment of iron deficiency anemia in CKD and end-stage kidney disease","volume":"6","author":"Guti\u00e9rrez","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.01.029_bib11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ekir.2025.01.029_bib12","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2025.01.029_bib13","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.01.029_bib14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2025.01.029_bib15","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.01.029_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2025.01.029_bib17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41598-023-28440-3","article-title":"Maintenance intravenous iron in hemodialysis patients to minimize erythropoietin doses: A double-blinded, randomized controlled trial (the MAINTAIN IRON trial)","volume":"13","author":"Anumas","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.01.029_bib18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1681\/ASN.V113530","article-title":"Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients","volume":"11","author":"Besarab","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12882-021-02308-y","article-title":"A\u00a0multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status","volume":"22","author":"Bhandari","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1681\/ASN.2018101016","article-title":"A\u00a0pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD","volume":"30","author":"Block","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A\u00a012-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3\u20135","volume":"65","author":"Block","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.01.029_bib22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/ndt\/gfs528","article-title":"Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: A randomized, active-controlled, multi-center study","volume":"28","author":"Charytan","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients\u2019 Response to IV Iron with Elevated ferritin (DRIVE) Study","volume":"18","author":"Coyne","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib24","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib25","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/ndt\/gfv277","article-title":"Ferric pyrophosphate citrate (Triferic\u2122) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients","volume":"30","author":"Fishbane","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib26","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ki.2015.203","article-title":"Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients","volume":"88","author":"Gupta","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.01.029_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10157-017-1510-x","article-title":"Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency","volume":"22","author":"Iguchi","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/nep.12891","article-title":"Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study","volume":"22","author":"Koiwa","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2025.01.029_bib30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2025.01.029_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2215\/CJN.02630608","article-title":"Iron-magnesium hydroxycarbonate (fermagate): A novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients","volume":"4","author":"McIntyre","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib32","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.ajkd.2021.03.020","article-title":"Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: A randomized trial and open-label extension","volume":"78","author":"Pergola","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.01.029_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/2054358120933397","article-title":"Effect of maintenance intravenous iron treatment on erythropoietin dose in chronic hemodialysis patients: A multicenter randomized controlled trial","volume":"7","author":"Susantitaphong","year":"2020","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.ekir.2025.01.029_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5414\/CN108924","article-title":"The safety of achieved iron stores and their effect on IV iron and ESA use: Post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis","author":"Umanath","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.628","article-title":"A\u00a0pharmacist-managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial","volume":"8","author":"van den Oever","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ekir.2025.01.029_bib36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2215\/CJN.05170513","article-title":"Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD","volume":"9","author":"Yokoyama","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib37","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s12325-021-01826-3","article-title":"The impact of intravenous iron supplementation on hematinic parameters and erythropoietin requirements in hemodialysis patients","volume":"38","author":"Zununi","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.ekir.2025.01.029_bib38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A\u00a0randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.01.029_bib39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000096174","article-title":"A\u00a0randomized controlled trial of oral versus intravenous iron in chronic kidney disease","volume":"26","author":"Agarwal","year":"2006","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib40","first-page":"170","article-title":"Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin","volume":"51","author":"Aggarwal","year":"2003","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.ekir.2025.01.029_bib41","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/ndt\/gfv293","article-title":"A\u00a0randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia","volume":"31","author":"Kalra","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib42","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib43","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ndt\/gfp584","article-title":"Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: A randomized controlled trial","volume":"25","author":"McMahon","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfu357","article-title":"Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial","volume":"30","author":"Pisani","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib45","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1111\/j.1523-1755.2005.00758.x","article-title":"A\u00a0randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD","volume":"68","author":"Van Wyck","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.01.029_bib46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2215\/CJN.06020710","article-title":"Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial","volume":"6","author":"Agarwal","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib47","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1093\/ndt\/gfs372","article-title":"A\u00a0randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial","volume":"27","author":"Barraclough","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: The FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib49","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/ndt\/gfv096","article-title":"A\u00a0randomized, open-label trial of iron isomaltoside 1000 (Monofer\u00ae) compared with iron sucrose (Venofer\u00ae) as maintenance therapy in haemodialysis patients","volume":"30","author":"Bhandari","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib50","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2215\/CJN.03850321","article-title":"Comparison of iron dosing strategies in patients undergoing long-term hemodialysis: A randomized controlled trial","volume":"16","author":"Bielesz","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.23876\/j.krcp.20.120","article-title":"The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: A randomized controlled pilot study","volume":"40","author":"Kassianides","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.ekir.2025.01.029_bib52","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ndt\/16.6.1239","article-title":"A\u00a0randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo","volume":"16","author":"Kosch","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5414\/CN109512","article-title":"Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial","volume":"91","author":"Macdougall","year":"2019","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib54","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial","volume":"29","author":"Onken","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib55","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000516012","article-title":"Ferric citrate dosing in iron deficiency anemia in nondialysis-dependent chronic kidney disease","volume":"52","author":"Pergola","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41598-022-26589-x","article-title":"A\u00a0randomized trial of once daily versus twice daily dosing of oral iron in CKD","volume":"13","author":"Sood","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.01.029_bib57","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/ckj\/sfac146","article-title":"Left ventricular dysfunction with preserved ejection fraction: The most common left ventricular disorder in chronic kidney disease patients","volume":"15","author":"Mark","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.01.029_bib58","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: The FAIR-HFpEF trial","volume":"45","author":"von Haehling","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2025.01.029_bib59","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/ndt\/gfaa008","article-title":"Identifying critically important cardiovascular outcomes for trials in hemodialysis: An international survey with patients, caregivers and health professionals","volume":"35","author":"O\u2019Lone","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.01.029_bib60","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A\u00a0trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2025.01.029_bib61","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2025.01.029_bib62","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1681\/ASN.2019090972","article-title":"Intravenous iron dosing and infection risk in patients on hemodialysis: A prespecified secondary analysis of the PIVOTAL trial","volume":"31","author":"Macdougall","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.01.029_bib63","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.26015","article-title":"Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA\/NEPHRO trials","volume":"96","author":"Wolf","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:00:42Z","timestamp":1747285242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2468024925000543"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.01.029","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}